Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ERBB2 /HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer

20 Jun 2025

Abstract excerpt

PURPOSE: HER2 targeting is increasingly relevant in metastatic urothelial cancer (mUC) because of emerging antibody-drug conjugates, in which assessment of tumor HER2/ERBB2 status could aid interpretation of ongoing trials. We evaluated whether precise ERBB2 genotype can be determined from mUC ctDNA and the relationship with tissue status. EXPERIMENTAL DESIGN: ERBB2 genotype was determined through targeted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bladder and Urothelial Cancer Treatments
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40540011
DOI: 10.1158/1078-0432.ccr-24-3912

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ERBB2 /HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial CancerPMID 40540011Read ↗

Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer.Semantic proximity Read ↗

Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.Semantic proximity Read ↗

Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer.Semantic proximity Read ↗

Characterizing the Genomic Landscape of the Micropapillary Subtype of Urothelial Carcinoma of the Bladder Harboring Activating Extracellular Mutations of ERBB2.Semantic proximity Read ↗

Molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinomaSemantic proximity Read ↗

Novel molecular biomarkers to guide treatment-decision making in metastatic urothelial cancer - A patient cohort analysisSemantic proximity Read ↗

Clinical utility of plasma ctDNA sequencing in metastatic urothelial cancer.Semantic proximity Read ↗

ctDNA Analysis in ERBB2 -Amplified Colorectal Cancer: Biomarker Analysis of the MyPathway TrialSemantic proximity Read ↗

Prevalence and complementary distribution of FGFR3 alterations and ERBB2 amplification in metastatic urothelial carcinoma: a nationwide registry analysis.Semantic proximity Read ↗

Novel Molecular Biomarkers to Guide Treatment Decision-making in Metastatic Urothelial Cancer-A Patient Cohort Analysis.Semantic proximity Read ↗

Clinical Outcomes, Genomic Heterogeneity, and Therapeutic Considerations Across Histologic Subtypes of Urothelial Carcinoma.Semantic proximity Read ↗

The genomic and transcriptomic landscape of metastastic urothelial cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.